Cargando…

Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance

Homoharringtonine- (HHT-) based HHT, aclarubicin, and cytarabine (HAA) induction regimen is the first-line therapy for nonelder acute myeloid leukemia (AML) patients in China. However, drug resistance is a new challenge, and little attention has been devoted to excavating resistant mechanisms. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Fenglin, Ling, Qing, Hu, Chao, Wang, Huafeng, Ye, Wenle, Li, Xia, Zhang, Xiang, Lin, Xiangjie, Wei, Wenwen, Huang, Xin, Qian, Yu, Zhuang, Haihui, Jin, Jie, Lu, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448541/ https://www.ncbi.nlm.nih.gov/pubmed/36081671 http://dx.doi.org/10.1155/2022/2813938

Ejemplares similares

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
por: Wei, Wenwen, et al.
Publicado: (2022)

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ITD
por: Qian, Yu, et al.
Publicado: (2023)

Identification of genetic variants or genes that are associated with Homoharringtonine (HHT) response through a genome-wide association study in human lymphoblastoid cell lines (LCLs)
por: Tong, Yin, et al.
Publicado: (2015)

A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia
por: Lévy, V, et al.
Publicado: (2006)

Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis
por: Li, Fenglin, et al.
Publicado: (2023)

Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines
por: Wang, Qian, et al.
Publicado: (2017)

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
por: Oiwa, Kana, et al.
Publicado: (2021)

MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway
por: Ling, Qing, et al.
Publicado: (2021)

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

Global, regional, and national burdens of leukemia from 1990 to 2017: a systematic analysis of the global burden of disease 2017 study
por: Lin, Xiangjie, et al.
Publicado: (2021)

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2019)

Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence
por: de Gussem, Els M., et al.
Publicado: (2020)

Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis
por: Zhang, Jing, et al.
Publicado: (2015)

Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
por: Zhu, Jun-Feng, et al.
Publicado: (2022)

Mononuclear cells and vascular repair in HHT
por: Dingenouts, Calinda K. E., et al.
Publicado: (2015)

Genotype–Phenotype Correlations in Children with HHT
por: Kilian, Alexandra, et al.
Publicado: (2020)

Homoharringtonine and omacetaxine for myeloid hematological malignancies
por: Lü, Shuqing, et al.
Publicado: (2014)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022)

Establishment and Characterization of a Newly Established Diabetic Gerbil Line
por: Li, Xiaohong, et al.
Publicado: (2016)

Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds
por: Marcos, Sol, et al.
Publicado: (2021)

Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism
por: Wang, Fenglin, et al.
Publicado: (2022)

P584: VENETOCLAX PLUS HOMOHARRINGTONINE-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADULTS WITH ACUTE MYELOID LEUKAEMIA: A MULTICENTRE, SINGLE-ARM, PHASE 2 TRIAL
por: Wang, Huafeng, et al.
Publicado: (2023)

The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019
por: Yao, Yiyi, et al.
Publicado: (2022)

Time heals all wounds—but 12-HHT is faster
por: Gus-Brautbar, Yael, et al.
Publicado: (2014)

Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT)
por: Zarrabeitia, Roberto, et al.
Publicado: (2017)

Classification of endonasal HHT lesions using digital microscopy
por: Haubner, F., et al.
Publicado: (2021)

Incidence of Spontaneous Pulmonary AVM Rupture in HHT Patients
por: Fish, Adam, et al.
Publicado: (2021)

Improved HHT-microstate analysis of EEG in nicotine addicts
por: Xiong, Xin, et al.
Publicado: (2023)

Dihydropyrimidinase‐like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia
por: Li, Fenglin, et al.
Publicado: (2023)

A case report of hepatopulmonary syndrome in hereditary hemorrhagic telangiectasia (HHT): Not all right-to-left shunting in HHT is due to pulmonary arteriovenous malformations
por: Krishnan, Sheila, et al.
Publicado: (2018)

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
por: Li, Jun, et al.
Publicado: (2022)

Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199
por: Mao, Shihui, et al.
Publicado: (2021)

Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence
por: Kilian, Alexandra, et al.
Publicado: (2020)

Individualized therapy of HHT driven by network analysis of metabolomic profiles
por: Jamshidi, Neema, et al.
Publicado: (2011)

Early detection of myocardial ischemia in resting ECG: analysis by HHT
por: Wang, Chun-Lin, et al.
Publicado: (2023)

Executive summary of the 14th HHT international scientific conference
por: Ola, Roxana, et al.
Publicado: (2023)

The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo
por: Dong, Hui-Jun, et al.
Publicado: (2018)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
por: Yuan, Fangfang, et al.
Publicado: (2022)

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine
por: Andersen, Petter I., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mlg2fn1kt1lksdadrvpv25n5ft